Document and Entity Information
Document and Entity Information Document - shares | 3 Months Ended | |
Mar. 31, 2020 | Apr. 30, 2020 | |
Document and Entity Information [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2020 | |
Document Transition Report | false | |
Entity File Number | 1-10864 | |
Entitiy Registrant Name | UnitedHealth Group Incorporated | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 41-1321939 | |
Entity Address, Address Line One | UnitedHealth Group Center | |
Entity Address, Address Line Two | 9900 Bren Road East | |
Entity Address, City or Town | Minnetonka, | |
Entity Address, State or Province | MN | |
Entity Address, Postal Zip Code | 55343 | |
City Area Code | 952 | |
Local Phone Number | 936-1300 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Title of 12(b) Security | Common Stock, $.01 par value | |
Trading Symbol | UNH | |
Security Exchange Name | NYSE | |
Entitiy Central Index Key | 0000731766 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Common Stock, Shares Outstanding | 948,379,502 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 21,569 | $ 10,985 |
Short-term investments | 2,876 | 3,260 |
Accounts receivable, net | 14,613 | 11,822 |
Other current receivables, net | 10,275 | 9,640 |
Assets under management | 2,866 | 3,076 |
Prepaid expenses and other current assets | 6,608 | 3,851 |
Total current assets | 58,807 | 42,634 |
Long-term investments | 36,578 | 37,209 |
Property, equipment and capitalized software, net | 8,173 | 8,704 |
Goodwill | 65,302 | 65,659 |
Other intangible assets, net | 10,199 | 10,349 |
Other assets | 10,008 | 9,334 |
Total assets | 189,067 | 173,889 |
Current liabilities: | ||
Medical costs payable | 22,772 | 21,690 |
Accounts payable and accrued liabilities | 22,845 | 19,005 |
Short-term borrowings and current maturities of long-term debt | 15,828 | 3,870 |
Unearned revenues | 2,509 | 2,622 |
Other current liabilities | 14,652 | 14,595 |
Total current liabilities | 78,606 | 61,782 |
Long-term debt, less current maturities | 35,779 | 36,808 |
Deferred income taxes | 3,030 | 2,993 |
Other liabilities | 10,048 | 10,144 |
Total liabilities | 127,463 | 111,727 |
Commitments and contingencies (Note 6) | ||
Redeemable noncontrolling interests | 1,741 | 1,726 |
Equity: | ||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.01 par value - 3,000 shares authorized; 947 and 948 issued and outstanding | 10 | 9 |
Additional Paid in Capital | 0 | 7 |
Retained earnings | 62,327 | 61,178 |
Accumulated other comprehensive loss | (5,360) | (3,578) |
Nonredeemable noncontrolling interests | 2,886 | 2,820 |
Total equity | 59,863 | 60,436 |
Total liabilities, redeemable noncontrolling interests and equity | $ 189,067 | $ 173,889 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheet (Parenthetical) - $ / shares shares in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 3,000 | 3,000 |
Common stock, shares issued | 947 | 948 |
Common stock, shares outstanding | 947 | 948 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10 | 10 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenues: | ||
Premiums | $ 50,640 | $ 47,513 |
Products | 8,431 | 8,072 |
Services | 4,985 | 4,318 |
Investment and other income | 365 | 405 |
Total revenues | 64,421 | 60,308 |
Operating costs: | ||
Medical costs | 41,000 | 38,939 |
Operating costs | 10,015 | 8,517 |
Cost of products sold | 7,687 | 7,381 |
Depreciation and amortization | 723 | 639 |
Total operating costs | 59,425 | 55,476 |
Earnings from operations | 4,996 | 4,832 |
Interest expense | (437) | (400) |
Earnings before income taxes | 4,559 | 4,432 |
Provision for income taxes | (1,094) | (875) |
Net earnings | 3,465 | 3,557 |
Earnings attributable to noncontrolling interests | (83) | (90) |
Net earnings attributable to UnitedHealth Group common shareholders | $ 3,382 | $ 3,467 |
Earnings per share attributable to UnitedHealth Group common shareholders: | ||
Basic | $ 3.56 | $ 3.62 |
Diluted | $ 3.52 | $ 3.56 |
Basic weighted-average number of common shares outstanding | 949 | 958 |
Dilutive effect of common share equivalents | 13 | 17 |
Diluted weighted-average number of common shares outstanding | 962 | 975 |
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | 10 | 8 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Net earnings | $ 3,465 | $ 3,557 |
Other comprehensive (loss) income: | ||
Gross unrealized (losses) gains on investment securities during the period | (349) | 520 |
Income tax effect | 80 | (119) |
Total unrealized (losses) gains, net of tax | (269) | 401 |
Gross reclassification adjustment for net realized (gains) losses included in net earnings | (18) | 4 |
Income tax effect | 4 | (1) |
Total reclassification adjustment, net of tax | (14) | 3 |
Total foreign currency translation losses | (1,499) | (2) |
Other comprehensive (loss) income | (1,782) | 402 |
Comprehensive income | 1,683 | 3,959 |
Comprehensive income attributable to noncontrolling interests | (83) | (90) |
Comprehensive income attributable to UnitedHealth Group common shareholders | $ 1,600 | $ 3,869 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions | Total | Common Stock [Member] | Additional Paid-In Capital [Member] | Retained Earnings [Member] | Net Unrealized (Losses) Gains on Investments [Member] | Foreign Currency Translation [Member] | Nonredeemable Noncontrolling Interests [Member] |
Balance at Dec. 31, 2018 | $ 54,319 | $ 10 | $ 0 | $ 55,846 | $ (264) | $ (3,896) | $ 2,623 |
Balance (Adjustment to adopt ASU 2016-02) at Dec. 31, 2018 | (18) | (13) | (5) | ||||
Balance (in shares) at Dec. 31, 2018 | 960 | ||||||
Net earnings attributable to UnitedHealth Group common shareholders | 3,467 | 3,467 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 60 | ||||||
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 3,527 | ||||||
Other comprehensive income (loss) | 402 | 404 | (2) | ||||
Issuances of common stock, and related tax effects (in shares) | 5 | ||||||
Issuances of common stock, and related tax effects | 56 | $ 0 | 56 | ||||
Share-based compensation | 239 | 239 | |||||
Common share repurchases (in shares) | (12) | ||||||
Common share repurchases | (3,002) | $ 0 | (34) | (2,968) | |||
Cash dividends paid on common shares | (860) | (860) | |||||
Redeemable noncontrolling interests fair value and other adjustments | (152) | (152) | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 23 | (109) | 132 | ||||
Distribution to nonredeemable noncontrolling interests | (83) | (83) | |||||
Balance at Mar. 31, 2019 | 54,451 | $ 10 | 0 | 55,472 | 140 | (3,898) | 2,727 |
Balance (in shares) at Mar. 31, 2019 | 953 | ||||||
Balance at Dec. 31, 2019 | 60,436 | $ 9 | 7 | 61,178 | 589 | (4,167) | 2,820 |
Balance (Adjustment to Adopt ASU 2016-13) at Dec. 31, 2019 | $ (28) | (28) | |||||
Balance (in shares) at Dec. 31, 2019 | 948 | 948 | |||||
Net earnings attributable to UnitedHealth Group common shareholders | $ 3,382 | 3,382 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 59 | ||||||
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 3,441 | ||||||
Other comprehensive income (loss) | (1,782) | (283) | (1,499) | ||||
Issuances of common stock, and related tax effects (in shares) | 5 | ||||||
Issuances of common stock, and related tax effects | 321 | $ 1 | 320 | ||||
Share-based compensation | 234 | 234 | |||||
Common share repurchases (in shares) | (6) | ||||||
Common share repurchases | (1,691) | $ 0 | (510) | (1,181) | |||
Cash dividends paid on common shares | (1,024) | (1,024) | |||||
Redeemable noncontrolling interests fair value and other adjustments | (51) | (51) | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 50 | 50 | |||||
Distribution to nonredeemable noncontrolling interests | (43) | (43) | |||||
Balance at Mar. 31, 2020 | $ 59,863 | $ 10 | $ 0 | $ 62,327 | $ 306 | $ (5,666) | $ 2,886 |
Balance (in shares) at Mar. 31, 2020 | 947 | 947 |
Condensed Consolidated Statem_4
Condensed Consolidated Statement of Changes in Equity (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Statement of Stockholders' Equity [Abstract] | ||
Common Stock, Dividends, Per Share, Cash Paid | $ 1.08 | $ 0.90 |
Payments of Ordinary Dividends, Common Stock | $ 1,024 | $ 860 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Operating activities | ||
Net earnings | $ 3,465 | $ 3,557 |
Noncash items: | ||
Depreciation and amortization | 723 | 639 |
Deferred income taxes | 202 | 134 |
Share-based compensation | 231 | 243 |
Other, net | 45 | 42 |
Net change in other operating items, net of effects from acquisitions and changes in AARP balances: | ||
Accounts receivable | (2,652) | (1,421) |
Other assets | (4,249) | (1,495) |
Medical costs payable | 1,120 | 1,125 |
Accounts payable and other liabilities | 4,137 | 318 |
Unearned revenues | (79) | 92 |
Cash flows from operating activities | 2,943 | 3,234 |
Investing activities | ||
Purchases of investments | (3,866) | (3,540) |
Sales of investments | 2,170 | 1,510 |
Maturities of investments | 1,726 | 1,711 |
Cash paid for acquisitions, net of cash assumed | (929) | (689) |
Purchases of property, equipment and capitalized software | (469) | (562) |
Other, net | (165) | 154 |
Cash flows used for investing activities | (1,533) | (1,416) |
Financing activities | ||
Common share repurchases | (1,691) | (3,002) |
Cash dividends paid | (1,024) | (860) |
Proceeds from common stock issuances | 557 | 323 |
Repayments of long-term debt | 0 | (1,250) |
Proceeds from short-term borrowings, net | 10,797 | 3,101 |
Customer funds administered | 1,062 | 1,784 |
Other, net | (398) | (368) |
Cash flows from (used for) financing activities | 9,303 | (272) |
Effect of exchange rate changes on cash and cash equivalents | (129) | (5) |
Increase in cash and cash equivalents | 10,584 | 1,541 |
Cash and cash equivalents, beginning of period | 10,985 | 10,866 |
Cash and cash equivalents, end of period | $ 21,569 | $ 12,407 |
Basis of Presentation (Notes)
Basis of Presentation (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Basis of Presentation UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone. Through its diversified family of businesses, the Company leverages core competencies in data and health information; advanced technology; and clinical expertise. These core competencies are deployed within two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum. The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC ( 2019 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly. Use of Estimates These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenue from Products For the quarter ended March 31, 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its OptumRx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member’s applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-13, “Financial Instruments - Credit Losses (Topic 326)” (ASU 2016-13). ASU 2016-13 requires the use of the current expected credit loss impairment model to develop an estimate of expected credit losses for certain financial assets. ASU 2016-13 also requires expected credit losses on available-for-sale debt securities to be recognized through an allowance for credit losses and revises certain disclosure requirements. The Company adopted ASU 2016-13 on January 1, 2020 using a cumulative effect upon adoption approach. The adoption of ASU 2016-13 was immaterial to the Company’s consolidated balance sheet, results of operations, equity and cash flows. Under the current expected credit loss impairment model, the Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances that may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements. |
Investments (Notes)
Investments (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Investments [Abstract] | |
Investments [Text Block] | Investments A summary of debt securities by major security type is as follows: (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2020 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,146 $ 183 $ (1 ) $ 3,328 State and municipal obligations 5,724 214 (20 ) 5,918 Corporate obligations 17,923 182 (411 ) 17,694 U.S. agency mortgage-backed securities 6,508 260 — 6,768 Non-U.S. agency mortgage-backed securities 1,932 28 (36 ) 1,924 Total debt securities - available-for-sale 35,233 867 (468 ) 35,632 Debt securities - held-to-maturity: U.S. government and agency obligations 410 9 — 419 State and municipal obligations 31 2 — 33 Corporate obligations 284 — (1 ) 283 Total debt securities - held-to-maturity 725 11 (1 ) 735 Total debt securities $ 35,958 $ 878 $ (469 ) $ 36,367 December 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,502 $ 55 $ (4 ) $ 3,553 State and municipal obligations 5,680 251 (5 ) 5,926 Corporate obligations 17,910 343 (11 ) 18,242 U.S. agency mortgage-backed securities 6,425 109 (6 ) 6,528 Non-U.S. agency mortgage-backed securities 1,811 37 (3 ) 1,845 Total debt securities - available-for-sale 35,328 795 (29 ) 36,094 Debt securities - held-to-maturity: U.S. government and agency obligations 402 2 — 404 State and municipal obligations 32 2 — 34 Corporate obligations 538 — (1 ) 537 Total debt securities - held-to-maturity 972 4 (1 ) 975 Total debt securities $ 36,300 $ 799 $ (30 ) $ 37,069 The Company held $1.7 billion and $2.0 billion of equity securities as of March 31, 2020 and December 31, 2019 , respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.4 billion of equity method investments in operating businesses in the health care sector as of March 31, 2020 and December 31, 2019 . The allowance for credit losses on held-to-maturity securities at March 31, 2020 was not material. The amortized cost and fair value of debt securities as of March 31, 2020 , by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Cost Fair Value Amortized Fair Due in one year or less $ 3,010 $ 3,011 $ 319 $ 320 Due after one year through five years 11,565 11,604 352 359 Due after five years through ten years 8,563 8,669 28 28 Due after ten years 3,655 3,656 26 28 U.S. agency mortgage-backed securities 6,508 6,768 — — Non-U.S. agency mortgage-backed securities 1,932 1,924 — — Total debt securities $ 35,233 $ 35,632 $ 725 $ 735 The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Value Gross Unrealized Losses Fair Value Gross Fair Value Gross March 31, 2020 Debt securities - available-for-sale: U.S. government and agency obligations $ 56 $ (1 ) $ — $ — $ 56 $ (1 ) State and municipal obligations 810 (20 ) — — 810 (20 ) Corporate obligations 9,294 (382 ) 391 (29 ) 9,685 (411 ) Non-U.S. agency mortgage-backed securities 841 (33 ) 30 (3 ) 871 (36 ) Total debt securities - available-for-sale $ 11,001 $ (436 ) $ 421 $ (32 ) $ 11,422 $ (468 ) December 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ 616 $ (4 ) $ — $ — $ 616 $ (4 ) State and municipal obligations 440 (5 ) — — 440 (5 ) Corporate obligations 1,903 (7 ) 740 (4 ) 2,643 (11 ) U.S. agency mortgage-backed securities 657 (3 ) 333 (3 ) 990 (6 ) Non-U.S. agency mortgage-backed securities 406 (3 ) — — 406 (3 ) Total debt securities - available-for-sale $ 4,022 $ (22 ) $ 1,073 $ (7 ) $ 5,095 $ (29 ) The Company’s unrealized losses from debt securities as of March 31, 2020 were generated from approximately 10,000 positions out of a total of 32,000 positions. The Company believes that it will collect the timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, and the potential economic impacts of COVID-19 on the issuers, noting no significant credit deterioration since purchase. As of March 31, 2020 , the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at March 31, 2020 was not material. |
Fair Value (Notes)
Fair Value (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value [Text Block] | Fair Value Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K. The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair and Carrying Value March 31, 2020 Cash and cash equivalents $ 21,450 $ 119 $ — $ 21,569 Debt securities - available-for-sale: U.S. government and agency obligations 3,143 185 — 3,328 State and municipal obligations — 5,918 — 5,918 Corporate obligations 59 17,385 250 17,694 U.S. agency mortgage-backed securities — 6,768 — 6,768 Non-U.S. agency mortgage-backed securities — 1,924 — 1,924 Total debt securities - available-for-sale 3,202 32,180 250 35,632 Equity securities 1,394 19 — 1,413 Assets under management 937 1,890 39 2,866 Total assets at fair value $ 26,983 $ 34,208 $ 289 $ 61,480 Percentage of total assets at fair value 44 % 56 % — % 100 % December 31, 2019 Cash and cash equivalents $ 10,837 $ 148 $ — $ 10,985 Debt securities - available-for-sale: U.S. government and agency obligations 3,369 184 — 3,553 State and municipal obligations — 5,926 — 5,926 Corporate obligations 70 17,923 249 18,242 U.S. agency mortgage-backed securities — 6,528 — 6,528 Non-U.S. agency mortgage-backed securities — 1,845 — 1,845 Total debt securities - available-for-sale 3,439 32,406 249 36,094 Equity securities 1,734 22 — 1,756 Assets under management 1,123 1,918 35 3,076 Total assets at fair value $ 17,133 $ 34,494 $ 284 $ 51,911 Percentage of total assets at fair value 33 % 66 % 1 % 100 % There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2020 or 2019 . The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair Value Total Carrying Value March 31, 2020 Debt securities - held-to-maturity $ 556 $ 91 $ 88 $ 735 $ 725 Long-term debt and other financing obligations $ — $ 45,272 $ — $ 45,272 $ 40,394 December 31, 2019 Debt securities - held-to-maturity $ 541 $ 181 $ 253 $ 975 $ 972 Long-term debt and other financing obligations $ — $ 45,078 $ — $ 45,078 $ 40,278 Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during either the three months ended March 31, 2020 or 2019 . |
Medical Costs Payable (Notes)
Medical Costs Payable (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Medical Costs Payable Text Block | Medical Costs Payable The following table shows the components of the change in medical costs payable for the three months ended March 31: (in millions) 2020 2019 Medical costs payable, beginning of period $ 21,690 $ 19,891 Acquisitions — 35 Reported medical costs: Current year 41,580 39,239 Prior years (580 ) (300 ) Total reported medical costs 41,000 38,939 Medical payments: Payments for current year (23,471 ) (22,973 ) Payments for prior years (16,447 ) (14,753 ) Total medical payments (39,918 ) (37,726 ) Medical costs payable, end of period $ 22,772 $ 21,139 For the three months ended March 31, 2020 , prior years medical cost reserve development was primarily driven by lower than expected health system utilization. For the three months ended March 31, 2019 , the prior years medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to the Company of $14.3 billion and $13.8 billion at March 31, 2020 and December 31, 2019 |
Short-Term Borrowings and Long-
Short-Term Borrowings and Long-Term Debt (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Commercial Paper and Long-Term Debt [Text Block] | and Long-Term Debt Short-term borrowings and senior unsecured long-term debt consisted of the following: March 31, 2020 December 31, 2019 (in millions, except percentages) Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value Commercial paper $ 1,214 $ 1,213 $ 1,213 $ 400 $ 400 $ 400 Bank credit facilities 10,000 10,000 10,000 — — — 2.700% notes due July 2020 1,500 1,500 1,500 1,500 1,499 1,506 Floating rate notes due October 2020 300 300 296 300 300 300 3.875% notes due October 2020 450 452 452 450 450 455 1.950% notes due October 2020 900 899 900 900 899 900 4.700% notes due February 2021 400 406 407 400 403 410 2.125% notes due March 2021 750 749 750 750 749 753 Floating rate notes due June 2021 350 349 347 350 349 350 3.150% notes due June 2021 400 399 406 400 399 407 3.375% notes due November 2021 500 510 512 500 501 512 2.875% notes due December 2021 750 768 764 750 753 765 2.875% notes due March 2022 1,100 1,114 1,130 1,100 1,087 1,121 3.350% notes due July 2022 1,000 998 1,034 1,000 998 1,036 2.375% notes due October 2022 900 896 912 900 896 911 0.000% notes due November 2022 15 13 14 15 13 14 2.750% notes due February 2023 625 646 640 625 624 638 2.875% notes due March 2023 750 797 777 750 770 770 3.500% notes due June 2023 750 747 788 750 747 786 3.500% notes due February 2024 750 746 794 750 746 792 2.375% notes due August 2024 750 747 767 750 747 760 3.750% notes due July 2025 2,000 1,991 2,161 2,000 1,990 2,161 3.700% notes due December 2025 300 298 323 300 298 325 3.100% notes due March 2026 1,000 996 1,056 1,000 996 1,048 3.450% notes due January 2027 750 746 804 750 746 804 3.375% notes due April 2027 625 620 668 625 620 667 2.950% notes due October 2027 950 939 992 950 939 988 3.850% notes due June 2028 1,150 1,143 1,281 1,150 1,142 1,269 3.875% notes due December 2028 850 843 953 850 843 941 2.875% notes due August 2029 1,000 1,104 1,047 1,000 993 1,029 4.625% notes due July 2035 1,000 992 1,190 1,000 992 1,215 5.800% notes due March 2036 850 838 1,107 850 838 1,129 6.500% notes due June 2037 500 492 691 500 492 712 6.625% notes due November 2037 650 641 910 650 641 940 6.875% notes due February 2038 1,100 1,077 1,613 1,100 1,076 1,631 3.500% notes due August 2039 1,250 1,241 1,348 1,250 1,241 1,313 5.700% notes due October 2040 300 296 405 300 296 396 5.950% notes due February 2041 350 345 484 350 345 475 4.625% notes due November 2041 600 589 742 600 589 716 4.375% notes due March 2042 502 484 601 502 484 580 3.950% notes due October 2042 625 608 711 625 607 688 4.250% notes due March 2043 750 735 885 750 735 856 4.750% notes due July 2045 2,000 1,973 2,547 2,000 1,973 2,463 4.200% notes due January 2047 750 738 881 750 738 861 4.250% notes due April 2047 725 717 853 725 717 839 3.750% notes due October 2047 950 934 1,050 950 934 1,023 4.250% notes due June 2048 1,350 1,330 1,592 1,350 1,330 1,569 4.450% notes due December 2048 1,100 1,086 1,333 1,100 1,086 1,316 3.700% notes due August 2049 1,250 1,235 1,385 1,250 1,235 1,344 3.875% notes due August 2059 1,250 1,229 1,372 1,250 1,228 1,350 Total short-term borrowings and long-term debt $ 50,631 $ 50,509 $ 55,388 $ 39,817 $ 39,474 $ 44,234 The Company’s long-term debt obligations also included $1.1 billion and $1.2 billion of other financing obligations, of which $309 million and $322 million were classified as current as of March 31, 2020 and December 31, 2019 , respectively. Commercial Paper and Bank Credit Facilities Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of March 31, 2020 , the Company’s outstanding commercial paper had a weighted average annual interest rate of 2.4% . The Company has $4.4 billion five-year, $4.4 billion three-year and $3.8 billion 364-day revolving bank credit facilities with 25 banks, which mature in December 2024 , December 2022 and December 2020 , respectively. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. As of March 31, 2020 , the Company had drawn $1.8 billion , $4.4 billion and $3.8 billion at annual interest rates of 1.6% , 1.6% and 1.7% on its $4.4 billion five-year, $4.4 billion three-year and $3.8 billion 364-day revolving bank credit facilities, respectively. Debt Covenants The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60% . The Company was in compliance with its debt covenants as of March 31, 2020 . |
Commitments and Contingencies (
Commitments and Contingencies (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Commitments and Contingencies Legal Matters Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices. The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred. Government Investigations, Audits and Reviews The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans. On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status. |
Segment Financial Information (
Segment Financial Information (Notes) | 3 Months Ended |
Mar. 31, 2020 | |
Segment Reporting [Abstract] | |
Segment Financial Information [Text Block] | Segment Financial Information The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx . For more information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K. The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare OptumHealth OptumInsight OptumRx Optum Eliminations Optum Corporate and Consolidated Three Months Ended March 31, 2020 Revenues - unaffiliated customers: Premiums $ 48,593 $ 2,047 $ — $ — $ — $ 2,047 $ — $ 50,640 Products — 9 29 8,393 — 8,431 — 8,431 Services 2,278 1,548 891 268 — 2,707 — 4,985 Total revenues - unaffiliated customers 50,871 3,604 920 8,661 — 13,185 — 64,056 Total revenues - affiliated customers — 5,452 1,562 12,876 (404 ) 19,486 (19,486 ) — Investment and other income 197 136 12 20 — 168 — 365 Total revenues $ 51,068 $ 9,192 $ 2,494 $ 21,557 $ (404 ) $ 32,839 $ (19,486 ) $ 64,421 Earnings from operations $ 2,888 $ 712 $ 536 $ 860 $ — $ 2,108 $ — $ 4,996 Interest expense — — — — — — (437 ) (437 ) Earnings before income taxes $ 2,888 $ 712 $ 536 $ 860 $ — $ 2,108 $ (437 ) $ 4,559 Three Months Ended March 31, 2019 Revenues - unaffiliated customers: Premiums $ 46,501 $ 1,012 $ — $ — $ — $ 1,012 $ — $ 47,513 Products — 8 23 8,041 — 8,072 — 8,072 Services 2,141 1,274 754 149 — 2,177 — 4,318 Total revenues - unaffiliated customers 48,642 2,294 777 8,190 — 11,261 — 59,903 Total revenues - affiliated customers — 4,287 1,407 9,613 (359 ) 14,948 (14,948 ) — Investment and other income 254 132 5 14 — 151 — 405 Total revenues $ 48,896 $ 6,713 $ 2,189 $ 17,817 $ (359 ) $ 26,360 $ (14,948 ) $ 60,308 Earnings from operations $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ — $ 4,832 Interest expense — — — — — — (400 ) (400 ) Earnings before income taxes $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ (400 ) $ 4,432 |
Basis of Presentation Basis of
Basis of Presentation Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Basis of presentation [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC ( 2019 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. |
Revenue [Policy Text Block] | Revenue from Products For the quarter ended March 31, 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its OptumRx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member’s applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-13, “Financial Instruments - Credit Losses (Topic 326)” (ASU 2016-13). ASU 2016-13 requires the use of the current expected credit loss impairment model to develop an estimate of expected credit losses for certain financial assets. ASU 2016-13 also requires expected credit losses on available-for-sale debt securities to be recognized through an allowance for credit losses and revises certain disclosure requirements. The Company adopted ASU 2016-13 on January 1, 2020 using a cumulative effect upon adoption approach. The adoption of ASU 2016-13 was immaterial to the Company’s consolidated balance sheet, results of operations, equity and cash flows. Under the current expected credit loss impairment model, the Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances that may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements. |
Investments (Policies)
Investments (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Investments [Abstract] | |
Investment, Policy [Policy Text Block] | At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, and the potential economic impacts of COVID-19 on the issuers, noting no significant credit deterioration since purchase. As of March 31, 2020 |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Short-Term and Long-Term Investments [Table Text Block] | A summary of debt securities by major security type is as follows: (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2020 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,146 $ 183 $ (1 ) $ 3,328 State and municipal obligations 5,724 214 (20 ) 5,918 Corporate obligations 17,923 182 (411 ) 17,694 U.S. agency mortgage-backed securities 6,508 260 — 6,768 Non-U.S. agency mortgage-backed securities 1,932 28 (36 ) 1,924 Total debt securities - available-for-sale 35,233 867 (468 ) 35,632 Debt securities - held-to-maturity: U.S. government and agency obligations 410 9 — 419 State and municipal obligations 31 2 — 33 Corporate obligations 284 — (1 ) 283 Total debt securities - held-to-maturity 725 11 (1 ) 735 Total debt securities $ 35,958 $ 878 $ (469 ) $ 36,367 December 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,502 $ 55 $ (4 ) $ 3,553 State and municipal obligations 5,680 251 (5 ) 5,926 Corporate obligations 17,910 343 (11 ) 18,242 U.S. agency mortgage-backed securities 6,425 109 (6 ) 6,528 Non-U.S. agency mortgage-backed securities 1,811 37 (3 ) 1,845 Total debt securities - available-for-sale 35,328 795 (29 ) 36,094 Debt securities - held-to-maturity: U.S. government and agency obligations 402 2 — 404 State and municipal obligations 32 2 — 34 Corporate obligations 538 — (1 ) 537 Total debt securities - held-to-maturity 972 4 (1 ) 975 Total debt securities $ 36,300 $ 799 $ (30 ) $ 37,069 |
Investments by Contractual Maturity [Table Text Block] | The amortized cost and fair value of debt securities as of March 31, 2020 , by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Cost Fair Value Amortized Fair Due in one year or less $ 3,010 $ 3,011 $ 319 $ 320 Due after one year through five years 11,565 11,604 352 359 Due after five years through ten years 8,563 8,669 28 28 Due after ten years 3,655 3,656 26 28 U.S. agency mortgage-backed securities 6,508 6,768 — — Non-U.S. agency mortgage-backed securities 1,932 1,924 — — Total debt securities $ 35,233 $ 35,632 $ 725 $ 735 |
Fair Value of Available-for-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time that Individual Securities have been in a Continuous Unrealized Loss Position [Table Text Block] | The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Value Gross Unrealized Losses Fair Value Gross Fair Value Gross March 31, 2020 Debt securities - available-for-sale: U.S. government and agency obligations $ 56 $ (1 ) $ — $ — $ 56 $ (1 ) State and municipal obligations 810 (20 ) — — 810 (20 ) Corporate obligations 9,294 (382 ) 391 (29 ) 9,685 (411 ) Non-U.S. agency mortgage-backed securities 841 (33 ) 30 (3 ) 871 (36 ) Total debt securities - available-for-sale $ 11,001 $ (436 ) $ 421 $ (32 ) $ 11,422 $ (468 ) December 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ 616 $ (4 ) $ — $ — $ 616 $ (4 ) State and municipal obligations 440 (5 ) — — 440 (5 ) Corporate obligations 1,903 (7 ) 740 (4 ) 2,643 (11 ) U.S. agency mortgage-backed securities 657 (3 ) 333 (3 ) 990 (6 ) Non-U.S. agency mortgage-backed securities 406 (3 ) — — 406 (3 ) Total debt securities - available-for-sale $ 4,022 $ (22 ) $ 1,073 $ (7 ) $ 5,095 $ (29 ) |
Fair Value (Tables)
Fair Value (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block] | The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair and Carrying Value March 31, 2020 Cash and cash equivalents $ 21,450 $ 119 $ — $ 21,569 Debt securities - available-for-sale: U.S. government and agency obligations 3,143 185 — 3,328 State and municipal obligations — 5,918 — 5,918 Corporate obligations 59 17,385 250 17,694 U.S. agency mortgage-backed securities — 6,768 — 6,768 Non-U.S. agency mortgage-backed securities — 1,924 — 1,924 Total debt securities - available-for-sale 3,202 32,180 250 35,632 Equity securities 1,394 19 — 1,413 Assets under management 937 1,890 39 2,866 Total assets at fair value $ 26,983 $ 34,208 $ 289 $ 61,480 Percentage of total assets at fair value 44 % 56 % — % 100 % December 31, 2019 Cash and cash equivalents $ 10,837 $ 148 $ — $ 10,985 Debt securities - available-for-sale: U.S. government and agency obligations 3,369 184 — 3,553 State and municipal obligations — 5,926 — 5,926 Corporate obligations 70 17,923 249 18,242 U.S. agency mortgage-backed securities — 6,528 — 6,528 Non-U.S. agency mortgage-backed securities — 1,845 — 1,845 Total debt securities - available-for-sale 3,439 32,406 249 36,094 Equity securities 1,734 22 — 1,756 Assets under management 1,123 1,918 35 3,076 Total assets at fair value $ 17,133 $ 34,494 $ 284 $ 51,911 Percentage of total assets at fair value 33 % 66 % 1 % 100 % |
Fair Value Measurements, Nonrecurring [Table Text Block] | The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair Value Total Carrying Value March 31, 2020 Debt securities - held-to-maturity $ 556 $ 91 $ 88 $ 735 $ 725 Long-term debt and other financing obligations $ — $ 45,272 $ — $ 45,272 $ 40,394 December 31, 2019 Debt securities - held-to-maturity $ 541 $ 181 $ 253 $ 975 $ 972 Long-term debt and other financing obligations $ — $ 45,078 $ — $ 45,078 $ 40,278 |
Medical Costs Payable (Tables)
Medical Costs Payable (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Insurance [Abstract] | |
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] | The following table shows the components of the change in medical costs payable for the three months ended March 31: (in millions) 2020 2019 Medical costs payable, beginning of period $ 21,690 $ 19,891 Acquisitions — 35 Reported medical costs: Current year 41,580 39,239 Prior years (580 ) (300 ) Total reported medical costs 41,000 38,939 Medical payments: Payments for current year (23,471 ) (22,973 ) Payments for prior years (16,447 ) (14,753 ) Total medical payments (39,918 ) (37,726 ) Medical costs payable, end of period $ 22,772 $ 21,139 |
Short-Term Borrowings and Lon_2
Short-Term Borrowings and Long-Term Debt (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Debt Instrument [Line Items] | |
Commercial Paper and Long-Term Debt [Table Text Block] | and senior unsecured long-term debt consisted of the following: March 31, 2020 December 31, 2019 (in millions, except percentages) Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value Commercial paper $ 1,214 $ 1,213 $ 1,213 $ 400 $ 400 $ 400 Bank credit facilities 10,000 10,000 10,000 — — — 2.700% notes due July 2020 1,500 1,500 1,500 1,500 1,499 1,506 Floating rate notes due October 2020 300 300 296 300 300 300 3.875% notes due October 2020 450 452 452 450 450 455 1.950% notes due October 2020 900 899 900 900 899 900 4.700% notes due February 2021 400 406 407 400 403 410 2.125% notes due March 2021 750 749 750 750 749 753 Floating rate notes due June 2021 350 349 347 350 349 350 3.150% notes due June 2021 400 399 406 400 399 407 3.375% notes due November 2021 500 510 512 500 501 512 2.875% notes due December 2021 750 768 764 750 753 765 2.875% notes due March 2022 1,100 1,114 1,130 1,100 1,087 1,121 3.350% notes due July 2022 1,000 998 1,034 1,000 998 1,036 2.375% notes due October 2022 900 896 912 900 896 911 0.000% notes due November 2022 15 13 14 15 13 14 2.750% notes due February 2023 625 646 640 625 624 638 2.875% notes due March 2023 750 797 777 750 770 770 3.500% notes due June 2023 750 747 788 750 747 786 3.500% notes due February 2024 750 746 794 750 746 792 2.375% notes due August 2024 750 747 767 750 747 760 3.750% notes due July 2025 2,000 1,991 2,161 2,000 1,990 2,161 3.700% notes due December 2025 300 298 323 300 298 325 3.100% notes due March 2026 1,000 996 1,056 1,000 996 1,048 3.450% notes due January 2027 750 746 804 750 746 804 3.375% notes due April 2027 625 620 668 625 620 667 2.950% notes due October 2027 950 939 992 950 939 988 3.850% notes due June 2028 1,150 1,143 1,281 1,150 1,142 1,269 3.875% notes due December 2028 850 843 953 850 843 941 2.875% notes due August 2029 1,000 1,104 1,047 1,000 993 1,029 4.625% notes due July 2035 1,000 992 1,190 1,000 992 1,215 5.800% notes due March 2036 850 838 1,107 850 838 1,129 6.500% notes due June 2037 500 492 691 500 492 712 6.625% notes due November 2037 650 641 910 650 641 940 6.875% notes due February 2038 1,100 1,077 1,613 1,100 1,076 1,631 3.500% notes due August 2039 1,250 1,241 1,348 1,250 1,241 1,313 5.700% notes due October 2040 300 296 405 300 296 396 5.950% notes due February 2041 350 345 484 350 345 475 4.625% notes due November 2041 600 589 742 600 589 716 4.375% notes due March 2042 502 484 601 502 484 580 3.950% notes due October 2042 625 608 711 625 607 688 4.250% notes due March 2043 750 735 885 750 735 856 4.750% notes due July 2045 2,000 1,973 2,547 2,000 1,973 2,463 4.200% notes due January 2047 750 738 881 750 738 861 4.250% notes due April 2047 725 717 853 725 717 839 3.750% notes due October 2047 950 934 1,050 950 934 1,023 4.250% notes due June 2048 1,350 1,330 1,592 1,350 1,330 1,569 4.450% notes due December 2048 1,100 1,086 1,333 1,100 1,086 1,316 3.700% notes due August 2049 1,250 1,235 1,385 1,250 1,235 1,344 3.875% notes due August 2059 1,250 1,229 1,372 1,250 1,228 1,350 Total short-term borrowings and long-term debt $ 50,631 $ 50,509 $ 55,388 $ 39,817 $ 39,474 $ 44,234 |
Segment Financial Information_2
Segment Financial Information (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Segment Reporting [Abstract] | |
Segment Financial Information [Table Text Block] | Optum (in millions) UnitedHealthcare OptumHealth OptumInsight OptumRx Optum Eliminations Optum Corporate and Consolidated Three Months Ended March 31, 2020 Revenues - unaffiliated customers: Premiums $ 48,593 $ 2,047 $ — $ — $ — $ 2,047 $ — $ 50,640 Products — 9 29 8,393 — 8,431 — 8,431 Services 2,278 1,548 891 268 — 2,707 — 4,985 Total revenues - unaffiliated customers 50,871 3,604 920 8,661 — 13,185 — 64,056 Total revenues - affiliated customers — 5,452 1,562 12,876 (404 ) 19,486 (19,486 ) — Investment and other income 197 136 12 20 — 168 — 365 Total revenues $ 51,068 $ 9,192 $ 2,494 $ 21,557 $ (404 ) $ 32,839 $ (19,486 ) $ 64,421 Earnings from operations $ 2,888 $ 712 $ 536 $ 860 $ — $ 2,108 $ — $ 4,996 Interest expense — — — — — — (437 ) (437 ) Earnings before income taxes $ 2,888 $ 712 $ 536 $ 860 $ — $ 2,108 $ (437 ) $ 4,559 Three Months Ended March 31, 2019 Revenues - unaffiliated customers: Premiums $ 46,501 $ 1,012 $ — $ — $ — $ 1,012 $ — $ 47,513 Products — 8 23 8,041 — 8,072 — 8,072 Services 2,141 1,274 754 149 — 2,177 — 4,318 Total revenues - unaffiliated customers 48,642 2,294 777 8,190 — 11,261 — 59,903 Total revenues - affiliated customers — 4,287 1,407 9,613 (359 ) 14,948 (14,948 ) — Investment and other income 254 132 5 14 — 151 — 405 Total revenues $ 48,896 $ 6,713 $ 2,189 $ 17,817 $ (359 ) $ 26,360 $ (14,948 ) $ 60,308 Earnings from operations $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ — $ 4,832 Interest expense — — — — — — (400 ) (400 ) Earnings before income taxes $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ (400 ) $ 4,432 |
Basis of Presentation Basis o_2
Basis of Presentation Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Details) | Jan. 01, 2020 |
Accounting Standards Update 2016-13 [Member] | |
Change in Accounting Principle, Accounting Standards Update, Retrospective Application Impracticable [true false] | true |
Investments (Narrative) (Detail
Investments (Narrative) (Details) number in Thousands, $ in Billions | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Investments [Abstract] | ||
Equity Securities, FV-NI and without Readily Determinable Fair Value | $ 1.7 | $ 2 |
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | 10 | |
Total number of security positions | 32 | |
Equity Method Investments | $ 1.4 | $ 1.4 |
Investments (Short-Term and Lon
Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | $ 35,233 | $ 35,328 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 867 | 795 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (468) | (29) |
Debt Securities, Available-for-sale | 35,632 | 36,094 |
Held-to-maturity securities, Amortized Cost | 725 | 972 |
Securities, Held to maturity, Unrecognized Holding Gain | 11 | 4 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (1) | (1) |
Debt Securities, Held-to-maturity, Fair Value | 735 | 975 |
Total debt securities, Amortized Cost | 35,958 | 36,300 |
Total debt securities, Gross Unrealized Gains | 878 | 799 |
Total debt securities, Gross Unrealized Losses | (469) | (30) |
Debt securities, Fair Value Disclosure | 36,367 | 37,069 |
Debt Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale | 35,632 | 36,094 |
U.S. Government and Agency Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 3,146 | 3,502 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 183 | 55 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (1) | (4) |
Debt Securities, Available-for-sale | 3,328 | 3,553 |
Held-to-maturity securities, Amortized Cost | 410 | 402 |
Securities, Held to maturity, Unrecognized Holding Gain | 9 | 2 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | 0 | 0 |
Debt Securities, Held-to-maturity, Fair Value | 419 | 404 |
State and Municipal Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 5,724 | 5,680 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 214 | 251 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (20) | (5) |
Debt Securities, Available-for-sale | 5,918 | 5,926 |
Held-to-maturity securities, Amortized Cost | 31 | 32 |
Securities, Held to maturity, Unrecognized Holding Gain | 2 | 2 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | 0 | 0 |
Debt Securities, Held-to-maturity, Fair Value | 33 | 34 |
Corporate Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 17,923 | 17,910 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 182 | 343 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (411) | (11) |
Debt Securities, Available-for-sale | 17,694 | 18,242 |
Held-to-maturity securities, Amortized Cost | 284 | 538 |
Securities, Held to maturity, Unrecognized Holding Gain | 0 | 0 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (1) | (1) |
Debt Securities, Held-to-maturity, Fair Value | 283 | 537 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 6,508 | 6,425 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 260 | 109 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | 0 | (6) |
Debt Securities, Available-for-sale | 6,768 | 6,528 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 1,932 | 1,811 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 28 | 37 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (36) | (3) |
Debt Securities, Available-for-sale | $ 1,924 | $ 1,845 |
Investments (Amortized Cost and
Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Schedule of Investments [Line Items] | ||
Due in one year or less, Amortized Cost | $ 3,010 | |
Due after one year through five years, Amortized Cost | 11,565 | |
Due after five years through ten years, Amortized Cost | 8,563 | |
Due after ten years, Amortized Cost | 3,655 | |
Total debt securities - available-for-sale, Amortized Cost | 35,233 | $ 35,328 |
Due in one year or less, Fair Value | 3,011 | |
Due after one year through five years, Fair Value | 11,604 | |
Due after five years through ten years, Fair Value | 8,669 | |
Due after ten years, Fair Value | 3,656 | |
Debt Securities, Available-for-sale | 35,632 | 36,094 |
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | 319 | |
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | 352 | |
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | 28 | |
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | 26 | |
Debt Securities, Held-to-maturity | 725 | 972 |
Held-to-maturity Securities, Debt Maturities, within One Year, Fair Value | 320 | |
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | 359 | |
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | 28 | |
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | 28 | |
Debt Securities, Held-to-maturity, Fair Value | 735 | 975 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Mortgage-backed securities, Amortized Cost | 6,508 | |
Total debt securities - available-for-sale, Amortized Cost | 6,508 | 6,425 |
Mortgage-backed securities, Fair Value | 6,768 | |
Debt Securities, Available-for-sale | 6,768 | 6,528 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Mortgage-backed securities, Amortized Cost | 1,932 | |
Total debt securities - available-for-sale, Amortized Cost | 1,932 | 1,811 |
Mortgage-backed securities, Fair Value | 1,924 | |
Debt Securities, Available-for-sale | $ 1,924 | $ 1,845 |
Investments (Fair Value of Avai
Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Debt Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | $ 11,001 | $ 4,022 |
Less Than 12 Months, Gross Unrealized Losses | (436) | (22) |
Greater Than 12 Months, Fair Value | 421 | 1,073 |
Greater Than 12 Months, Gross Unrealized Losses | (32) | (7) |
Total, Fair Value | 11,422 | 5,095 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (468) | (29) |
U.S. Government and Agency Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 56 | 616 |
Less Than 12 Months, Gross Unrealized Losses | (1) | (4) |
Greater Than 12 Months, Fair Value | 0 | 0 |
Greater Than 12 Months, Gross Unrealized Losses | 0 | 0 |
Total, Fair Value | 56 | 616 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (1) | (4) |
State and Municipal Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 810 | 440 |
Less Than 12 Months, Gross Unrealized Losses | (20) | (5) |
Greater Than 12 Months, Fair Value | 0 | 0 |
Greater Than 12 Months, Gross Unrealized Losses | 0 | 0 |
Total, Fair Value | 810 | 440 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (20) | (5) |
Corporate Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 9,294 | 1,903 |
Less Than 12 Months, Gross Unrealized Losses | (382) | (7) |
Greater Than 12 Months, Fair Value | 391 | 740 |
Greater Than 12 Months, Gross Unrealized Losses | (29) | (4) |
Total, Fair Value | 9,685 | 2,643 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (411) | (11) |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 657 | |
Less Than 12 Months, Gross Unrealized Losses | (3) | |
Greater Than 12 Months, Fair Value | 333 | |
Greater Than 12 Months, Gross Unrealized Losses | (3) | |
Total, Fair Value | 990 | |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (6) | |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 841 | 406 |
Less Than 12 Months, Gross Unrealized Losses | (33) | (3) |
Greater Than 12 Months, Fair Value | 30 | 0 |
Greater Than 12 Months, Gross Unrealized Losses | (3) | 0 |
Total, Fair Value | 871 | 406 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | $ (36) | $ (3) |
Fair Value (Narrative) (Details
Fair Value (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Fair Value [Line Items] | ||
Transfers Into Level 3 | $ 0 | $ 0 |
Transfers out of Level 3 | 0 | 0 |
Fair Value, Nonrecurring [Member] | ||
Fair Value [Line Items] | ||
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis | $ 0 | $ 0 |
Fair Value (Financial Assets an
Fair Value (Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | $ 21,569 | $ 10,985 |
Debt Securities, Available-for-sale | 35,632 | 36,094 |
Equity Securities, Fair Value | 1,413 | 1,756 |
Assets under management | 2,866 | 3,076 |
Assets, Fair Value Disclosure | 61,480 | 51,911 |
Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 35,632 | 36,094 |
U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,328 | 3,553 |
State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 5,918 | 5,926 |
Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 17,694 | 18,242 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 6,768 | 6,528 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 1,924 | 1,845 |
Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 21,450 | 10,837 |
Equity Securities, Fair Value | 1,394 | 1,734 |
Assets under management | 937 | 1,123 |
Assets, Fair Value Disclosure | 26,983 | 17,133 |
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,202 | 3,439 |
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,143 | 3,369 |
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 59 | 70 |
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 119 | 148 |
Equity Securities, Fair Value | 19 | 22 |
Assets under management | 1,890 | 1,918 |
Assets, Fair Value Disclosure | 34,208 | 34,494 |
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 32,180 | 32,406 |
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 185 | 184 |
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 5,918 | 5,926 |
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 17,385 | 17,923 |
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 6,768 | 6,528 |
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 1,924 | 1,845 |
Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Equity Securities, Fair Value | 0 | 0 |
Assets under management | 39 | 35 |
Assets, Fair Value Disclosure | 289 | 284 |
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 250 | 249 |
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 250 | 249 |
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 0 | $ 0 |
Fair Value (Financial Assets _2
Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | $ 735 | $ 975 |
Debt Securities, Held-to-maturity | 725 | 972 |
Debt and other financing obligations, carrying value | 50,509 | 39,474 |
Fair Value, Nonrecurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 735 | 975 |
Debt and other financing obligations | 45,272 | 45,078 |
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 556 | 541 |
Debt and other financing obligations | 0 | 0 |
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 91 | 181 |
Debt and other financing obligations | 45,272 | 45,078 |
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 88 | 253 |
Debt and other financing obligations | 0 | 0 |
Long-term debt and other financing obligations | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations, carrying value | $ 40,394 | $ 40,278 |
Medical Costs Payable (Narrativ
Medical Costs Payable (Narrative) (Details) - USD ($) $ in Billions | Mar. 31, 2020 | Dec. 31, 2019 |
Liability for Claims and Claims Adjustment Expense [Line Items] | ||
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount | $ 14.3 | $ 13.8 |
Medical Costs Payable Rollforwa
Medical Costs Payable Rollforward (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items] | ||
Medical costs payable, beginning of period | $ 21,690 | $ 19,891 |
Acquisitions | 0 | 35 |
Reported medical costs: | ||
Current year | 41,580 | 39,239 |
Prior years | (580) | (300) |
Total reported medical costs | 41,000 | 38,939 |
Medical payments: | ||
Payments for current year | (23,471) | (22,973) |
Payments for prior years | (16,447) | (14,753) |
Total medical payments | (39,918) | (37,726) |
Medical costs payable, end of period | $ 22,772 | $ 21,139 |
Short-Term Borrowings and Lon_3
Short-Term Borrowings and Long-Term Debt (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | |
Debt Instrument [Line Items] | ||
Bank credit facilities | $ 10,000 | $ 0 |
Five year $4.4 billion credit facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Credit Facility, Maximum Borrowing Capacity | 4,400 | |
Bank credit facilities | $ 1,800 | |
Line of Credit Facility, Interest Rate at Period End | 1.60% | |
Line of Credit Facility, Expiration Period | 5 years | |
Three year $4.4 billion credit facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 4,400 | |
Bank credit facilities | $ 4,400 | |
Line of Credit Facility, Interest Rate at Period End | 1.60% | |
Line of Credit Facility, Expiration Period | 3 years | |
364 day $3.8 billion credit facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 3,800 | |
Bank credit facilities | $ 3,800 | |
Line of Credit Facility, Interest Rate at Period End | 1.70% | |
Line of Credit Facility, Expiration Period | 364 days | |
Subsidiaries [Member] | ||
Debt Instrument [Line Items] | ||
Other Long-term Debt | $ 1,100 | 1,200 |
Other Long-term Debt, Current | $ 309 | $ 322 |
Commercial Paper [Member] | ||
Debt Instrument [Line Items] | ||
Short-term Debt, Weighted Average Interest Rate, at Point in Time | 2.40% |
Short-Term Borrowings and Lon_4
Short-Term Borrowings and Long-Term Debt (Details) - USD ($) $ in Millions | Mar. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Bank credit facilities | $ 10,000 | $ 0 |
Par Value | 50,631 | 39,817 |
Carrying value, Combined Amount | 50,509 | 39,474 |
Fair Value | 55,388 | 44,234 |
Commercial Paper [Member] | ||
Debt Instrument [Line Items] | ||
Commercial Paper | 1,213 | 400 |
Par Value | 1,214 | 400 |
Fair Value | $ 1,213 | 400 |
2.700% Notes due July 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.70% | |
Par Value | $ 1,500 | 1,500 |
Carrying Value, Current | 1,500 | 1,499 |
Fair Value | 1,500 | 1,506 |
Floating rate notes due October 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | 300 | 300 |
Carrying Value, Current | 300 | 300 |
Fair Value | $ 296 | 300 |
3.875% notes due October 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Par Value | $ 450 | 450 |
Carrying Value, Current | 452 | 450 |
Fair Value | $ 452 | 455 |
1.950% notes due October 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 1.95% | |
Par Value | $ 900 | 900 |
Carrying Value, Current | 899 | 899 |
Fair Value | $ 900 | 900 |
4.700% notes due February 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.70% | |
Par Value | $ 400 | 400 |
Carrying Value, Current | 406 | |
Carrying Value, Noncurrent | 403 | |
Fair Value | $ 407 | 410 |
2.125% notes due March 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.125% | |
Par Value | $ 750 | 750 |
Carrying Value, Current | 749 | |
Carrying Value, Noncurrent | 749 | |
Fair Value | 750 | 753 |
Floating rate notes due June 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | 350 | 350 |
Carrying Value, Noncurrent | 349 | 349 |
Fair Value | $ 347 | 350 |
3.150% notes due June 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.15% | |
Par Value | $ 400 | 400 |
Carrying Value, Noncurrent | 399 | 399 |
Fair Value | $ 406 | 407 |
3.375% notes due November 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.375% | |
Par Value | $ 500 | 500 |
Carrying Value, Noncurrent | 510 | 501 |
Fair Value | $ 512 | 512 |
2.875% notes due December 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 768 | 753 |
Fair Value | $ 764 | 765 |
2.875% notes due March 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 1,100 | 1,100 |
Carrying Value, Noncurrent | 1,114 | 1,087 |
Fair Value | $ 1,130 | 1,121 |
3.350% notes due July 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.35% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 998 | 998 |
Fair Value | $ 1,034 | 1,036 |
2.375% notes due October 2022 [Member] [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.375% | |
Par Value | $ 900 | 900 |
Carrying Value, Noncurrent | 896 | 896 |
Fair Value | $ 912 | 911 |
Zero Coupon notes due November 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | |
Par Value | $ 15 | 15 |
Carrying Value, Noncurrent | 13 | 13 |
Fair Value | $ 14 | 14 |
2.750% notes due February 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | |
Par Value | $ 625 | 625 |
Carrying Value, Noncurrent | 646 | 624 |
Fair Value | $ 640 | 638 |
2.875% notes due March 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 797 | 770 |
Fair Value | $ 777 | 770 |
3.500% notes due June 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 747 | 747 |
Fair Value | $ 788 | 786 |
3.500% notes due February 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 746 | 746 |
Fair Value | $ 794 | 792 |
2.375% notes due August 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.375% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 747 | 747 |
Fair Value | $ 767 | 760 |
3.750% notes due July 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | |
Par Value | $ 2,000 | 2,000 |
Carrying Value, Noncurrent | 1,991 | 1,990 |
Fair Value | $ 2,161 | 2,161 |
3.700% notes due December 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.70% | |
Par Value | $ 300 | 300 |
Carrying Value, Noncurrent | 298 | 298 |
Fair Value | $ 323 | 325 |
3.100% notes due March 2026 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.10% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 996 | 996 |
Fair Value | $ 1,056 | 1,048 |
3.450% notes due January 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.45% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 746 | 746 |
Fair Value | $ 804 | 804 |
3.375% notes due April 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.375% | |
Par Value | $ 625 | 625 |
Carrying Value, Noncurrent | 620 | 620 |
Fair Value | $ 668 | 667 |
2.950% notes due October 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.95% | |
Par Value | $ 950 | 950 |
Carrying Value, Noncurrent | 939 | 939 |
Fair Value | $ 992 | 988 |
3.850% notes due June 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.85% | |
Par Value | $ 1,150 | 1,150 |
Carrying Value, Noncurrent | 1,143 | 1,142 |
Fair Value | $ 1,281 | 1,269 |
3.875% notes due December 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Par Value | $ 850 | 850 |
Carrying Value, Noncurrent | 843 | 843 |
Fair Value | $ 953 | 941 |
2.875% notes due August 2029 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 1,104 | 993 |
Fair Value | $ 1,047 | 1,029 |
4.625% notes due July 2035 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.625% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 992 | 992 |
Fair Value | $ 1,190 | 1,215 |
5.800% notes due March 2036 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.80% | |
Par Value | $ 850 | 850 |
Carrying Value, Noncurrent | 838 | 838 |
Fair Value | $ 1,107 | 1,129 |
6.500% Notes Due June 2037 [Member] [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | |
Par Value | $ 500 | 500 |
Carrying Value, Noncurrent | 492 | 492 |
Fair Value | $ 691 | 712 |
6.625% Notes due November 2037 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.625% | |
Par Value | $ 650 | 650 |
Carrying Value, Noncurrent | 641 | 641 |
Fair Value | $ 910 | 940 |
6.875% notes due February 2038 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.875% | |
Par Value | $ 1,100 | 1,100 |
Carrying Value, Noncurrent | 1,077 | 1,076 |
Fair Value | $ 1,613 | 1,631 |
3.500% notes due August 2039 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Par Value | $ 1,250 | 1,250 |
Carrying Value, Noncurrent | 1,241 | 1,241 |
Fair Value | $ 1,348 | 1,313 |
5.700% notes due October 2040 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.70% | |
Par Value | $ 300 | 300 |
Carrying Value, Noncurrent | 296 | 296 |
Fair Value | $ 405 | 396 |
5.950% notes due February 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.95% | |
Par Value | $ 350 | 350 |
Carrying Value, Noncurrent | 345 | 345 |
Fair Value | $ 484 | 475 |
4.625% notes due November 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.625% | |
Par Value | $ 600 | 600 |
Carrying Value, Noncurrent | 589 | 589 |
Fair Value | $ 742 | 716 |
4.375% notes due March 2042 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.375% | |
Par Value | $ 502 | 502 |
Carrying Value, Noncurrent | 484 | 484 |
Fair Value | $ 601 | 580 |
3.950% notes due October 2042 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.95% | |
Par Value | $ 625 | 625 |
Carrying Value, Noncurrent | 608 | 607 |
Fair Value | $ 711 | 688 |
4.250% notes due March 2043 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 735 | 735 |
Fair Value | $ 885 | 856 |
4.750% notes due July 2045 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.75% | |
Par Value | $ 2,000 | 2,000 |
Carrying Value, Noncurrent | 1,973 | 1,973 |
Fair Value | $ 2,547 | 2,463 |
4.200% notes due January 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.20% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 738 | 738 |
Fair Value | $ 881 | 861 |
4.250% notes due April 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Par Value | $ 725 | 725 |
Carrying Value, Noncurrent | 717 | 717 |
Fair Value | $ 853 | 839 |
3.750% notes due October 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | |
Par Value | $ 950 | 950 |
Carrying Value, Noncurrent | 934 | 934 |
Fair Value | $ 1,050 | 1,023 |
4.250% notes due June 2048 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Par Value | $ 1,350 | 1,350 |
Carrying Value, Noncurrent | 1,330 | 1,330 |
Fair Value | $ 1,592 | 1,569 |
4.450% notes due December 2048 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.45% | |
Par Value | $ 1,100 | 1,100 |
Carrying Value, Noncurrent | 1,086 | 1,086 |
Fair Value | $ 1,333 | 1,316 |
3.700% notes due August 2049 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.70% | |
Par Value | $ 1,250 | 1,250 |
Carrying Value, Noncurrent | 1,235 | 1,235 |
Fair Value | $ 1,385 | 1,344 |
3.875% notes due August 2059 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Par Value | $ 1,250 | 1,250 |
Carrying Value, Noncurrent | 1,229 | 1,228 |
Fair Value | $ 1,372 | $ 1,350 |
Segment Financial Information_3
Segment Financial Information (Narrative) (Details) | 3 Months Ended |
Mar. 31, 2020 | |
Statement [Line Items] | |
Number of Reportable Segments | 4 |
Segment Financial Information_4
Segment Financial Information (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | $ 50,640 | $ 47,513 |
Products | 8,431 | 8,072 |
Services | 4,985 | 4,318 |
Investment and other income | 365 | 405 |
Total revenues | 64,421 | 60,308 |
Earnings from operations | 4,996 | 4,832 |
Interest expense | (437) | (400) |
Earnings before income taxes | 4,559 | 4,432 |
Optum | ||
Statement [Line Items] | ||
Investment and other income | 168 | 151 |
Total revenues | 32,839 | 26,360 |
Earnings from operations | 2,108 | 1,878 |
Interest expense | 0 | 0 |
Earnings before income taxes | 2,108 | 1,878 |
Unaffiliated Customers | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 50,640 | 47,513 |
Products | 8,431 | 8,072 |
Services | 4,985 | 4,318 |
Total revenues | 64,056 | 59,903 |
Unaffiliated Customers | Optum | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 2,047 | 1,012 |
Products | 8,431 | 8,072 |
Services | 2,707 | 2,177 |
Total revenues | 13,185 | 11,261 |
Affiliated Customers | ||
Statement [Line Items] | ||
Total revenues | 0 | 0 |
Affiliated Customers | Optum | ||
Statement [Line Items] | ||
Total revenues | 19,486 | 14,948 |
Operating Segments | UnitedHealthcare | ||
Statement [Line Items] | ||
Investment and other income | 197 | 254 |
Total revenues | 51,068 | 48,896 |
Earnings from operations | 2,888 | 2,954 |
Interest expense | 0 | 0 |
Earnings before income taxes | 2,888 | 2,954 |
Operating Segments | OptumHealth | ||
Statement [Line Items] | ||
Investment and other income | 136 | 132 |
Total revenues | 9,192 | 6,713 |
Earnings from operations | 712 | 626 |
Interest expense | 0 | 0 |
Earnings before income taxes | 712 | 626 |
Operating Segments | OptumInsight | ||
Statement [Line Items] | ||
Investment and other income | 12 | 5 |
Total revenues | 2,494 | 2,189 |
Earnings from operations | 536 | 432 |
Interest expense | 0 | 0 |
Earnings before income taxes | 536 | 432 |
Operating Segments | OptumRx | ||
Statement [Line Items] | ||
Investment and other income | 20 | 14 |
Total revenues | 21,557 | 17,817 |
Earnings from operations | 860 | 820 |
Interest expense | 0 | 0 |
Earnings before income taxes | 860 | 820 |
Operating Segments | Unaffiliated Customers | UnitedHealthcare | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 48,593 | 46,501 |
Products | 0 | 0 |
Services | 2,278 | 2,141 |
Total revenues | 50,871 | 48,642 |
Operating Segments | Unaffiliated Customers | OptumHealth | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 2,047 | 1,012 |
Products | 9 | 8 |
Services | 1,548 | 1,274 |
Total revenues | 3,604 | 2,294 |
Operating Segments | Unaffiliated Customers | OptumInsight | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products | 29 | 23 |
Services | 891 | 754 |
Total revenues | 920 | 777 |
Operating Segments | Unaffiliated Customers | OptumRx | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products | 8,393 | 8,041 |
Services | 268 | 149 |
Total revenues | 8,661 | 8,190 |
Operating Segments | Affiliated Customers | UnitedHealthcare | ||
Statement [Line Items] | ||
Total revenues | 0 | 0 |
Operating Segments | Affiliated Customers | OptumHealth | ||
Statement [Line Items] | ||
Total revenues | 5,452 | 4,287 |
Operating Segments | Affiliated Customers | OptumInsight | ||
Statement [Line Items] | ||
Total revenues | 1,562 | 1,407 |
Operating Segments | Affiliated Customers | OptumRx | ||
Statement [Line Items] | ||
Total revenues | 12,876 | 9,613 |
Optum Eliminations | ||
Statement [Line Items] | ||
Investment and other income | 0 | 0 |
Total revenues | (404) | (359) |
Earnings from operations | 0 | 0 |
Interest expense | 0 | 0 |
Earnings before income taxes | 0 | 0 |
Optum Eliminations | Unaffiliated Customers | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products | 0 | 0 |
Services | 0 | 0 |
Total revenues | 0 | 0 |
Optum Eliminations | Affiliated Customers | ||
Statement [Line Items] | ||
Total revenues | (404) | (359) |
Corporate and Eliminations | ||
Statement [Line Items] | ||
Investment and other income | 0 | 0 |
Total revenues | (19,486) | (14,948) |
Earnings from operations | 0 | 0 |
Interest expense | (437) | (400) |
Earnings before income taxes | (437) | (400) |
Corporate and Eliminations | Unaffiliated Customers | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products | 0 | 0 |
Services | 0 | 0 |
Total revenues | 0 | 0 |
Corporate and Eliminations | Affiliated Customers | ||
Statement [Line Items] | ||
Total revenues | $ (19,486) | $ (14,948) |